Home>News & Events

News & Events

  • December 18, 2018

    Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative

     Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA’s decision to accept the...
  • March 20, 2017

    Critical Path Institute Launches Type 1 Diabetes Consortium

     March 20, 2017 Critical Path Institute Launches Type 1 Diabetes Consortium Tucson, Ariz., March 20, 2017 –Critical Path Institute (C-Path) is pleased to announce the launch of the Type 1 Diabetes (T1D) Consortium. Funded by The Leona M. and Harry B. Helmsley Charitable Trust; Janssen Research & Development, LLC; JDRF International; and Sanofi, the T1D...
Refine:

Period

Program

  • All Programs
  • CPAD - Critical Path For Alzheimer's Disease
  • TTC - Transplant Therapeutics Consortium
  • T1D - Type 1 Diabetes Consortium
  • HD-RSC - Huntington’s Disease Regulatory Science Consortium
  • RDCA-DAP - Rare Disease Cures Accelerator-Data and Analytics Platform
  • CFAST - Coalition For Accelerating Standards and Therapies
  • BmDR - Biomarker Data Repository
  • CPP - Critical Path for Parkinson's
  • CPTR - Critical Path to TB Drug Regimens
  • DCC - Data Collaboration Center
  • D-RSC - Duchenne Regulatory Science Consortium
  • INC - International Neonatal Consortium
  • MSOAC - Multiple Sclerosis Outcome Assessments Consortium
  • PKD - Polycystic Kidney Disease Outcomes Consortium
  • PRO Consortium - Patient-Reported Outcome Consortium
  • ePRO Consortium - Electronic Patient-Reported Outcome Consortium
  • PSTC - Predictive Safety Testing Consortium
  • PTC - Pediatric Trials Consortium
  • TB-PACTS - TB-Platform for Aggregation of Clinical TB Studies

Category

Tags

x